Why the study?
Does ketanserin prolong the QT interval and affect vagal function in healthy subjects?
Does ketanserin prolong the QT interval and affect vagal function in healthy subjects?
Short-term ketanserin treatment in healthy subjects causes significant QTc interval prolongation and a reduction in heart rate, independent of enhanced cardiac parasympathetic activity.
Ketanserin use warrants QTc monitoring for proarrhythmic risk; extends direct evidence of its electrophysiologic effects to healthy subjects.
The serotonergic type-2 (5HT2) antagonist ketanserin was given in a dose of 40 mg twice daily for 3 days to eight healthy subjects in a double-blind placebo controlled randomized crossover study. 2. The QTc interval was prolonged slightly but significantly (P less than 0.01) by a mean of 29 +/- 7 milliseconds after ketanserin compared to placebo. 3. Ketanserin reduced both mean arterial pressure and heart rate (P less than 0.05), by 5.7 +/- 1.8 mmHg and 3.5 +/- 1.5 beats minute-1 respectively, when compared to placebo. 4. There was a tendency (not statistically significant) for cardiac vagal outflow to be reduced after ketanserin (assessed by the heart rate responses to standing, deep breathing and the Valsalva manoeuvre). 5. In healthy man, ketanserin causes prolongation of the QTc interval and a reduction in heart rate. These changes do not appear to be due to enhanced cardiac parasympathetic activity.
No takes yet. Share an insight, caveat, or question.
Stott et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: